Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5033MR)

This product GTTS-WQ5033MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5033MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11095MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ11373MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ15962MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ1160MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ6542MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ558MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2257MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ13802MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW